High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Parenteral iron is given to patients in a variety of formulations, including two iron dextran products known as high- (HMW) or low- (LMW) molecular weight iron dextran. Despite more risk of adverse events, HMW iron dextran is sometimes substituted for LMW iron dextran without physician knowledge for reasons of cost. A recent decision by the Centers for Medicare and Medicaid Services (CMS) to re-merge J-codes for both iron dextrans may increase the unintended use of HMW iron dextran, resulting perhaps in more adverse drug events. Physicians who use parenteral iron should be aware of these practices and actively participate in formulary decisions regarding their substitution. Recently, in Tennessee, a physician ordered LMW iron dextran (INFeD, Watson, Morristown, NJ) in a patient for iron deficiency anemia when oral iron had been ineffective and tolerated poorly. The pharmacist substituted the less expensive HMW iron dextran (Dexferrum, American Regent, Shirley, NY). Anaphylaxis shortly after receiving a test dose of HMW iron dextran was followed by death. Despite at least nine publications demonstrating higher rates of adverse drug events with HMW iron dextran1–9 and with no publications showing contradictory results, HMW iron dextran continues to be substituted by individuals seemingly unaware of the various risk profiles among products for intravenous iron replacement. In one of these studies, the adverse event rate following administration of HMW iron dextran was 28%.5 The reported total absolute rates of adverse drug events with parenteral iron are 38 per million doses, with life-threatening adverse drug events per million of 11.3 for HMW iron dextran, 3.3 for LMW dextran, 0.9 for ferric gluconate, and 0.6 for iron sucrose.10 Even more worrisome is the ready substitution of HMW for LMW iron dextran because of cost, which is not a rare event. We have personally documented such occurrences where clinicians ordered LMW iron dextran and HMW iron dextran was substituted in its place. In four confirmed instances where anaphylaxis did not result in death, LMW iron dextran was subsequently administered uneventfully. By the early 1990s, intravenous iron was used routinely to synergize with erythropoiesis stimulating agents (ESAs) for the treatment of dialysis-associated anemia. LMW and HMW iron dextrans were the only products available throughout the 1990s. In 1997, LMW iron dextran became unavailable for several months, necessitating the use of HMW iron dextran in virtually all dialysis patients requiring intravenous iron to support erythropoiesis. During that period, there was an 1100% increase in adverse drug events reported to the Food and Drug Administration (FDA) following administration of iron dextran according to data obtained through the Freedom of Information Act (obtained by M.A.). Subsequently, in 1998, the FDA declared LMW iron dextran “medically necessary” despite the widespread availability of the HMW product. The FDA definition of medically necessary is, “… if the product is used to treat or prevent a serious medical condition, and there is no other source of that product or alternative drug that is judged by medical staff to be an adequate substitute.” Today, other parenteral iron products are also relatively safer, including ferric gluconate and iron sucrose, although more expensive. In the first study to demonstrate the benefits of intravenous iron when used in conjunction with ESAs for chemotherapy-induced anemia, 79 patients received LMW iron dextran and two patients received HMW iron dextran.9 Although none of the 79 patients receiving LMW iron dextran experienced a serious adverse drug event, one of the two patients who received HMW iron dextran experienced anaphylaxis requiring intubation. Using data from the FDA MedWatch program, Chertow et al.3 determined that the rates of all, as well as life-threatening, adverse drug events were significantly higher among recipients of HMW versus LMW iron dextran or other nondextran iron products. Moreover, using conservative assumptions about the distribution of “iron dextran-associated” adverse drug events where product was not specified, the authors suggest the higher event rate observed with HMW iron dextran may be an underestimate. There also are two published studies in hemodialysis patients comparing LMW iron dextran to iron sucrose,10,11 generally considered by nephrologists to be safer than iron dextran, showing some10 or no difference in toxicity.11 In 2006, different J-codes, which are drug-specific codes used to bill CMS, were assigned to Dexferrum (HMW) and INFeD (LMW) iron dextrans. Providing different J-codes forced providers to discriminate between these products and allowed better tracking of drug-specific adverse reactions. In January 2008, CMS re-merged the J-codes for HMW and LMW iron dextran. For the majority of U.S. physicians who are unaware that two iron dextrans even exist, there is high likelihood that the lower-priced HMW ir
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the basis of this study was the general consensus that high molecular weight iron dextran complexes, most of which are no longer marketed, display higher rates and generally more severe hypersensitivity reactions [4,5,6].”
Citations
Cites
Uchino, S. (2005) · JAMA · doi:10.1001/jama.294.7.813 · Cited by 4,176
The Effect of Acute Renal Failure on Mortality: A Cohort Analysis
LEVY, E. M., VISCOLI, C. M., Horwitz, R. I., & Rich, G. F. (1996) · JAMA · doi:10.1001/jama.1996.03530430033035 · Cited by 1,794
The effect of acute renal failure on mortality. A cohort analysis
Levy, E. M. (1996) · JAMA · doi:10.1001/jama.275.19.1489 · Cited by 1,660
Ronco, C., Bellomo, R., Homel, P., Brendolan, A., Dan, M., Piccinni, P., & La Greca, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02430-2 · Cited by 1,594
Daily Hemodialysis and the Outcome of Acute Renal Failure
Schiffl, H., Lang, S. M., & Fischer, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010877 · Cited by 862
Incidence and Mortality of Acute Renal Failure in Medicare Beneficiaries, 1992 to 2001
Xue, J. L., Daniels, F., Star, R. A., Kimmel, P. L., Eggers, P. W., Molitoris, B. A., Himmelfarb, J., & Collins, A. J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005060668 · Cited by 765
Vinsonneau, C., Camus, C., Combes, A., Costa de Beauregard, M. A., Klouche, K., Boulain, T., Pallot, J.-L., Chiche, J.-D., Taupin, P., Landais, P., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69111-3 · Cited by 685
A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure
Mehta, R. L., for the Collaborative Group for Treatment of ARF in the ICU, Mcdonald, B., Gabbai, F. B., Pahl, M., Pascual, M. T. A., Farkas, A., & Kaplan, R. M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0600031154.x · Cited by 658
Declining Mortality in Patients with Acute Renal Failure, 1988 to 2002
Waikar, S. S., Curhan, G. C., Wald, R., McCarthy, E. P., & Chertow, G. M. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005091017 · Cited by 587
Self-citationCommunity-based incidence of acute renal failure
Hsu, C.-Y., McCulloch, C. E., Fan, D., Ordoñez, J. D., Chertow, G. M., & Go, A. S. (2007) · Kidney International · doi:10.1038/sj.ki.5002297 · Cited by 570
Self-citation
Cited by
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
Iron deficiency anaemia: pathophysiology, assessment, practical management
Kumar, A., Sharma, E., Marley, A., Samaan, M. A., & Brookes, M. J. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000759 · Cited by 344
ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjad108 · Cited by 318
Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
Auerbach, M., & Ballard, H. (2010) · Hematology · doi:10.1182/asheducation-2010.1.338 · Cited by 310
Self-citationDisorders of iron metabolism. Part II: iron deficiency and iron overload
Muñoz, M., García-Erce, J. A., & Remacha, Á. F. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.086991 · Cited by 292
Metadata
- Authors
- Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H.
- Affiliations
- University of Utah (US)
- Georgetown University (US)
- Northwestern University (US)
- Stanford University (US)
- Washington University in St. Louis (US)
- University of California, Los Angeles (US)
- Corresponding author
- Rodgers, George M.
- Henry, David H.
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2008-05
- Volume
- 19
- Issue
- 5
- Pages
- 833-834
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2109124986
- Cited by
- 56
- References
- 32
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- parenteral iron, drug substitution, adverse drug reactions, anaphylaxis, iron deficiency anemia, erythropoiesis-stimulating agents, formulary decisions, iron sucrose, ferric gluconate
- MeSH terms
- Anaphylaxis, Chemistry, Pharmaceutical, Hematinics, Humans, Iron-Dextran Complex, Molecular Weight, Drug Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing? https://app.cochat.ai/papers/10.1681/asn.2008030255
- The paper
- Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H. (2008). High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing? Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2008030255
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.